Search Results - elizabeth+jaffee

8 Results

Sort By:

Using CD29 as a Marker for Cell Identification in Single Cell Analysis

AbstractWith the advent of cancer immunology, mass cytometry has been increasingly employed to characterize the responses to cancer therapies and the tumor microenvironment (TME). One of its most notable applications is efficient multiplexing of samples into batches by dedicating a number of metal isotope channels to barcodes, enabling robust data acquisition...

Published: 9/27/2024 | Inventor(s): Won Jin Ho, Elizabeth Jaffee, Soren Charmsaz, Nicole Gross

Keywords(s):

Category(s):

miR-21 as a Therapy to Intercept Pancreatic Ductal Adenocarcinoma

Unmet NeedPancreatic ductal adenocarcinomas (PDAs) are the most prevalent neoplastic disease of the pancreas. PDAs account for more than 90% of all pancreatic malignancies and are the fourth most frequent cause of cancer-related deaths worldwide. Almost all PDAs develop following the activation of the KRAS gene. This activation triggers epithelial transformation...

Published: 9/27/2024 | Inventor(s): Elizabeth Jaffee, Nina Chu, Jacquelyn Zimmerman

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology > Pancreatic Ductal Adenocarcinoma

Targeting PTPN22 in Cancer Therapy

Unmet NeedTumor-infiltrating lymphocytes (TILs) such as B-cells, T-cells, and natural killers are gaining traction in anti-tumor immune responses. TILs involve the use of special immune cells called T-cells, otherwise known as lymphocytes, which protect the body from viral infections, fight cancer, and coordinate the activities of other cells during...

Published: 9/26/2024 | Inventor(s): Elizabeth Jaffee, Won Jin Ho, Soren Charmsaz

Keywords(s): Cancers, Combination, Discovery/Research Tools, Disease Indication, In Vivo Research Tool, Knock Out Mouse Model, Mouse Model, Target, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Research Tools > Animal Models

A DNAJB1-PRKACA fusion kinase peptide vaccine for patients with fibrolamellar hepatocellular carcinoma

Unmet NeedFibrolamellar carcinoma (FLC) is an extremely rare form of cancer. It affects both men and women in approximately 1 in 5,000,000 people with greater frequency among young adults with a median age of diagnosis of 25. Unfortunately, there is no standard of care therapy for this cancer, and patients with this disease have an expected median survival...

Published: 9/27/2024 | Inventor(s): Mark Yarchoan, Elizabeth Jaffee, Aditya Mohan

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology > Liver Cancer, Technology Classifications > Therapeutic Modalities > Vaccines, Technology Classifications > Therapeutic Modalities > Immunotherapies

BAFF Synergies with Anti-PD-1 Therapy to Promote Anti-tumor Immunity

Unmet NeedImmune checkpoint therapy has revolutionized how we think about and treat cancers; however, despite remarkable success, immuno-monotherapy has only provided a robust response in ~20-30% of tumors treated. Researchers are now exploring other treatment paradigms including cell, gene, and vaccine therapies to stimulate patents’ immune systems...

Published: 9/26/2024 | Inventor(s): Mark Yarchoan, Elizabeth Jaffee

Keywords(s):

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Immunotherapies, Clinical and Disease Specializations > Immuno-Oncology, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

PD-1/PD-L1 Blockade together with Vaccine Therapy Facilitates Effector T Cell Infiltration into Pancreatic Tumors

Novel Combination Therapy for Pancreatic Cancer TreatmentJHU REF: C12915Invention Novelty: The technology is the novel combination of PD1/PD-L1 blockade antibody and vaccine-based immunotherapy to treat pancreatic cancer.Value Proposition:Pancreatic cancer is one of the top cancer killers in the United States due to late detection and resistance to...

Published: 9/26/2024 | Inventor(s): Elizabeth Jaffee, Lei Zheng

Keywords(s): Biologics, Cancers, Combination, Disease Indication, Pancreatic Cancer, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Vaccine

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Vaccines, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

Discovery of Diagnostic Biomarkers and Therapeutic Targets for Pancreatic Cancer

C12251: Diagnostic Protein Biomarkers For Pancreatic CancerNovelty: This technology comprises the identification of three protein biomarkers, highly expressed in pancreatic cancer compared to normal pancreatic cells.Value Proposition: Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer-related death in the US. Thus there is an unmet...

Published: 9/26/2024 | Inventor(s): Darshil Jhaveri, Robert Anders, Elizabeth Jaffee

Keywords(s): Adenocarcinoma, Biomarker, Cancers, Clinical Diagnostics, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Mechanism-of-action Biomarker, Pancreatic Cancer, Pancreatic ductal adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Adenocarcinoma, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Clinical and Disease Specializations > Oncology > Pancreatic Ductal Adenocarcinoma, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

Annexin A2 is a Cancer Target Recognized by Antibodies and T Cells and is Involved in Cancer Development and Progression

C10569: Molecular Target to Diagnose & Treat Pancreatic Cancer & Methods to Identify New Targets Value Proposition: ADVANTAGES • Diagnostic and therapeutic target for pancreatic cancer • Molecular target to develop vaccines and antagonistic antibodies for therapy and prevention • Confirmed T cell response for robust, diverse,...

Published: 9/26/2024 | Inventor(s): Lanqing Huang, Lei Zheng, Elizabeth Jaffee

Keywords(s): Biomarker, Cancers, Disease Indication, Immunotherapy, Pancreatic Cancer, Pharmakodynamic Biomarker, Single, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology